48-Year-Old Man Presents With Diffuse Lymphadenopathy

Poll

A 48-year-old man presents with diffuse lymphadenopathy. After further evaluation, a biopsy is performed. What is your diagnosis?

According to the histopathology image below, what is your diagnosis? - See more at: http://www.oncotherapynetwork.com/image-iq/40-year-old-woman-presents-several-liver-nodules#sthash.BhY8QKnL.dpuf According to the histopathology image below, what is your diagnosis? - See more at: http://www.oncotherapynetwork.com/image-iq/40-year-old-woman-presents-several-liver-nodules#sthash.BhY8QKnL.dpuf

A 48-year-old man presents with diffuse lymphadenopathy. According to the histopathology image below, what is your diagnosis?

 

 

What is your diagnosis?

A. Diffuse large B-cell lymphoma
B. Hodgkin lymphoma
C. Follicular lymphoma
D. Dermatopathic lymphadenopathy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content